{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:16:11Z","timestamp":1788621371598,"version":"build-2803163510"},"reference-count":29,"publisher":"Japanese Society of Internal Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,1,15]]},"DOI":"10.2169\/internalmedicine.1640-23","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T22:14:29Z","timestamp":1685484869000},"page":"265-270","source":"Crossref","is-referenced-by-count":4,"title":["Renal Immune-related Adverse Event of Pembrolizumab Masked by Pemetrexed"],"prefix":"10.2169","volume":"63","author":[{"given":"Koya","family":"Nagase","sequence":"first","affiliation":[{"name":"Department of Nephrology, Chubu Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Murai","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Chubu Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waka","family":"Yokoyama-Kokuryo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Chubu Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Nagasaka","sequence":"additional","affiliation":[{"name":"Department of Pathology, Chubu Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Medicine, Immunology and Rheumatology, Mayo Clinic College of Medicine and Science, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Chubu Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Chubu Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumika","family":"Nagase","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Chubu Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Chubu Rosai Hospital, Japan"},{"name":"Department of Rheumatology, Chubu Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Dine J, Gordon R, Shames Y, Kasler MK, Barton-Burke M. Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer. Asia Pac J Oncol Nurs 4: 127-135, 2017.","DOI":"10.4103\/apjon.apjon_4_17"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel) 12: 738, 2020.","DOI":"10.3390\/cancers12030738"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small cell lung cancer. N Engl J Med 378: 2078-2092, 2018.","DOI":"10.1056\/NEJMoa1801005"},{"key":"4","unstructured":"4. Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20: 497-530, 2022."},{"key":"5","unstructured":"5. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36: 1714-1768, 2018."},{"key":"6","unstructured":"6. Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Canc Netw 17: 255-289, 2019."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39: 4073-4126, 2021.","DOI":"10.1200\/JCO.21.01440"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Mita AC, Sweeney CJ, Baker SD, et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 24: 552-562, 2006.","DOI":"10.1200\/JCO.2004.00.9720"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Cortazar FB, Kibbelaar ZA, Glezerman IG, et al. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol 31: 435-446, 2020.","DOI":"10.1681\/ASN.2019070676"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Perazella MA. Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol 7: 1713-1721, 2012.","DOI":"10.2215\/CJN.02780312"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Stavroulopoulos A, Nakopoulou L, Xydakis AM, Aresti V, Nikolakopoulou A, Klouvas G. Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed. Ren Fail 32: 1000-1004, 2010.","DOI":"10.3109\/0886022X.2010.501930"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Zattera T, Londrino F, Trezzi M, et al. Pemetrexed-induced acute kidney failure following irreversible renal damage: two case reports and literature review. J Nephropathol 6: 43-48, 2017.","DOI":"10.15171\/jnp.2017.07"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Glezerman IG, Pietanza MC, Miller V, Seshan SV. Kidney tubular toxicity of maintenance pemetrexed therapy. Am J Kidney Dis 58: 817-820, 2011.","DOI":"10.1053\/j.ajkd.2011.04.030"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Asai A, Katsuno T, Yamaguchi M, et al. Carboplatin-related acute interstitial nephritis in a patient with pancreatic neuroendocrine tumor. CEN Case Rep 9: 114-121, 2020.","DOI":"10.1007\/s13730-019-00437-w"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Spanou Z, Keller M, Britschgi M, et al. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol 17: 2919-2927, 2006.","DOI":"10.1681\/ASN.2006050418"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Perazella MA. Checkmate: kidney injury associated with targeted cancer immunotherapy. Kidney Int 90: 474-476, 2016.","DOI":"10.1016\/j.kint.2016.05.024"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Shirali AC, Perazella MA, Gettinger S. Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis 68: 287-291, 2016.","DOI":"10.1053\/j.ajkd.2016.02.057"},{"key":"18","unstructured":"18. Gupta S, Short SAP, Sise ME, et al. Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer 9: e003467, 2021."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Lee MD, Seethapathy H, Strohbehn IA, et al. Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study. J Immunother Cancer 9: e002292, 2021.","DOI":"10.1136\/jitc-2020-002292"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Seethapathy H, Zhao S, Chute DF, et al. The incidence, causes, and risk factors for acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol 14: 1692-1700, 2019.","DOI":"10.2215\/CJN.00990119"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Visser S, Huisbrink J, van't Veer NE, et al. Renal impairment during pemetrexed maintenance in patients with advanced non-small cell lung cancer: a cohort study. Eur Respir J 52: 1800884, 2018.","DOI":"10.1183\/13993003.00884-2018"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Sato Y, Oguchi A, Fukushima Y, et al. CD153\/CD30 signaling promotes age-dependent tertiary lymphoid tissue expansion and kidney injury. J Clin Invest 132: e146071, 2022.","DOI":"10.1172\/JCI146071"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Sato Y, Boor P, Fukuma S, et al. Developmental stages of tertiary lymphoid tissue reflect local injury and inflammation in mouse and human kidneys. Kidney Int 98: 448-463, 2020.","DOI":"10.1016\/j.kint.2020.02.023"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Dorraji SE, Kanapathippillai P, Hovd AK, et al. Kidney tertiary lymphoid structures in lupus nephritis develop into large interconnected networks and resemble lymph nodes in gene signature. Am J Pathol 190: 2203-2225, 2020.","DOI":"10.1016\/j.ajpath.2020.07.015"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Sato Y, Tamura M, Yanagita M. Tertiary lymphoid tissues: a regional hub for kidney inflammation. Nephrol Dial Transplant 38: 26-33, 2023.","DOI":"10.1093\/ndt\/gfab212"},{"key":"26","unstructured":"26. Singh S, Long JP, Tchakarov A, Dong Y, Yee C, Lin JS. Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis. JCI Insight. Forthcoming."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Lee YH, Sato Y, Saito M, et al. Advanced tertiary lymphoid tissues in protocol biopsies are associated with progressive graft dysfunction in kidney transplant recipients. J Am Soc Nephrol 33: 186-200, 2022.","DOI":"10.1681\/ASN.2021050715"},{"key":"28","doi-asserted-by":"crossref","first-page":"e87680","DOI":"10.1172\/jci.insight.87680","volume":"1","author":"Y Sato","year":"2016","unstructured":"28. Sato Y, Mii A, Hamazaki Y, et al. Heterogeneous fibroblasts underlie age-dependent tertiary lymphoid tissues in the kidney. JCI Insight 1: e87680, 2016.","journal-title":"JCI Insight","ISSN":"https:\/\/id.crossref.org\/issn\/2379-3708","issn-type":"print"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Cassol C, Satoskar A, Lozanski G, et al. Anti-PD-1 immunotherapy may induce interstitial nephritis with increased tubular epithelial expression of PD-L1. Kidney Int Rep 4: 1152-1160, 2019.","DOI":"10.1016\/j.ekir.2019.06.001"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/2\/63_1640-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:30:33Z","timestamp":1715574633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/2\/63_1640-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1640-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,15]]},"article-number":"1640-23"}}